A Biobank of Pediatric Patient-derived-xenograft Models in Cancer Precision Medicine Trial MAPPYACTS for Relapsed and Refractory Tumors

Pediatric patients with recurrent and refractory cancers are in most need for new treatments. This study developed patient-derived-xenograft (PDX) models within the European MAPPYACTS cancer precision medicine trial (NCT02613962). To date, 131 PDX models were established following heterotopical and/or orthotopical implantation in immunocompromised mice: 76 sarcomas, 25 other solid tumors, 12 central nervous system tumors, 15 acute leukemias, and 3 lymphomas. PDX establishment rate was 43%. Histology, whole exome and RNA sequencing revealed a high concordance with the primary patient's tumor profile, human leukocyte-antigen characteristics and specific metabolic pathway signatures. A detailed patient molecular characterization, including specific mutations prioritized in the clinical molecular tumor boards are provided. Ninety models were shared with the IMI2 ITCC Pediatric Preclinical Proof-of-concept Platform (IMI2 ITCC-P4) for further exploitation. This PDX biobank of unique recurrent childhood cancers provides an essential support for basic and translational research and treatments development in advanced pediatric malignancies.

Citing Articles

Patient-derived rhabdomyosarcoma cells recapitulate the genetic and transcriptomic landscapes of primary tumors.

Hu Y, He Z, Liu S, Ying W, Chen Y, Zhao M iScience. 2024; 27(10):110862.

PMID: 39319271 PMC: 11417342. DOI: 10.1016/j.isci.2024.110862.

Xenografting Human Musculoskeletal Sarcomas in Mice, Chick Embryo, and Zebrafish: How to Boost Translational Research.

Giusti V, Miserocchi G, Sbanchi G, Pannella M, Hattinger C, Cesari M Biomedicines. 2024; 12(8).

PMID: 39200384 PMC: 11352184. DOI: 10.3390/biomedicines12081921.

Pediatric Tumors as Disorders of Development: The Case for In Vitro Modeling Based on Human Stem Cells.

Clairmont C, Gell J, Lau C Cancer Control. 2024; 31:10732748241270564.

PMID: 39118322 PMC: 11311176. DOI: 10.1177/10732748241270564.

Biological Sample Collection to Advance Research and Treatment: A Fight Osteosarcoma Through European Research and Euro Ewing Consortium Statement.

Green D, Ewijk R, Tirtei E, Andreou D, Baecklund F, Baumhoer D Clin Cancer Res. 2024; 30(16):3395-3406.

PMID: 38869831 PMC: 11334773. DOI: 10.1158/1078-0432.CCR-24-0101.

Divergent HLA variations and heterogeneous expression but recurrent HLA loss-of- heterozygosity and common and transcriptional silencing across advanced pediatric solid cancers.

Lim W, Marques Da Costa M, Godefroy K, Jacquet E, Gragert L, Rondof W Front Immunol. 2024; 14:1265469.

PMID: 38318504 PMC: 10839790. DOI: 10.3389/fimmu.2023.1265469.

References

Harrington C, Sotillo E, Robert A, Hayer K, Bogusz A, Psathas J . Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma. Leukemia. 2019; 33(10):2429-2441. PMC: 6884148. DOI: 10.1038/s41375-019-0454-4. View

Rasmussen M, Harndahl M, Stryhn A, Boucherma R, Nielsen L, Lemonnier F . Uncovering the peptide-binding specificities of HLA-C: a general strategy to determine the specificity of any MHC class I molecule. J Immunol. 2014; 193(10):4790-802. PMC: 4226424. DOI: 10.4049/jimmunol.1401689. View

Vogelstein B, Kinzler K . The Path to Cancer --Three Strikes and You're Out. N Engl J Med. 2015; 373(20):1895-8. DOI: 10.1056/NEJMp1508811. View

Kim D, Paggi J, Park C, Bennett C, Salzberg S . Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat Biotechnol. 2019; 37(8):907-915. PMC: 7605509. DOI: 10.1038/s41587-019-0201-4. View

Tentler J, Tan A, Weekes C, Jimeno A, Leong S, Pitts T . Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012; 9(6):338-50. PMC: 3928688. DOI: 10.1038/nrclinonc.2012.61. View

Drost J, Clevers H . Organoids in cancer research. Nat Rev Cancer. 2018; 18(7):407-418. DOI: 10.1038/s41568-018-0007-6. View

Kawaguchi S, Higasa K, Shimizu M, Yamada R, Matsuda F . HLA-HD: An accurate HLA typing algorithm for next-generation sequencing data. Hum Mutat. 2017; 38(7):788-797. DOI: 10.1002/humu.23230. View

Houghton P, Morton C, Tucker C, Payne D, Favours E, Cole C . The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer. 2006; 49(7):928-40. DOI: 10.1002/pbc.21078. View

Richelle A, Kellman B, Wenzel A, Chiang A, Reagan T, Gutierrez J . Model-based assessment of mammalian cell metabolic functionalities using omics data. Cell Rep Methods. 2021; 1(3). PMC: 8577426. DOI: 10.1016/j.crmeth.2021.100040. View

10.

Burr M, Sparbier C, Chan K, Chan Y, Kersbergen A, Lam E . An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. Cancer Cell. 2019; 36(4):385-401.e8. PMC: 6876280. DOI: 10.1016/j.ccell.2019.08.008. View

11.

Boeva V, Louis-Brennetot C, Peltier A, Durand S, Pierre-Eugene C, Raynal V . Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries. Nat Genet. 2017; 49(9):1408-1413. DOI: 10.1038/ng.3921. View

12.

Bruna A, Rueda O, Greenwood W, Batra A, Callari M, Batra R . A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. Cell. 2016; 167(1):260-274.e22. PMC: 5037319. DOI: 10.1016/j.cell.2016.08.041. View

13.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

14.

McGranahan N, Swanton C . Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell. 2017; 168(4):613-628. DOI: 10.1016/j.cell.2017.01.018. View

15.

Woo X, Giordano J, Srivastava A, Zhao Z, Lloyd M, de Bruijn R . Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat Genet. 2021; 53(1):86-99. PMC: 7808565. DOI: 10.1038/s41588-020-00750-6. View

16.

Marques Da Costa M, Daudigeos-Dubus E, Gomez-Brouchet A, Bawa O, Rouffiac V, Serra M . Establishment and characterization of in vivo orthotopic bioluminescent xenograft models from human osteosarcoma cell lines in Swiss nude and NSG mice. Cancer Med. 2018; 7(3):665-676. PMC: 5852344. DOI: 10.1002/cam4.1346. View

17.

Laurent A, Siret A, Ignacimouttou C, Panchal K, Diop M, Jenni S . Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia. Clin Cancer Res. 2020; 26(13):3307-3318. PMC: 7334063. DOI: 10.1158/1078-0432.CCR-19-3519. View

18.

Adane B, Alexe G, Seong B, Lu D, Hwang E, Hnisz D . STAG2 loss rewires oncogenic and developmental programs to promote metastasis in Ewing sarcoma. Cancer Cell. 2021; 39(6):827-844.e10. PMC: 8378827. DOI: 10.1016/j.ccell.2021.05.007. View

19.

Brenneman M, Field A, Yang J, Williams G, Doros L, Rossi C . Temporal order of RNase IIIb and loss-of-function mutations during development determines phenotype in pleuropulmonary blastoma / syndrome: a unique variant of the two-hit tumor suppression model. F1000Res. 2018; 4:214. PMC: 4712775. DOI: 10.12688/f1000research.6746.2. View

20.

Hidalgo M, Amant F, Biankin A, Budinska E, Byrne A, Caldas C . Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014; 4(9):998-1013. PMC: 4167608. DOI: 10.1158/2159-8290.CD-14-0001. View